Principles and scope of this chapter

01Where This Series Stands

Pharmaceutical materials are born inside a web of outsourcing. Design from a production house, copy from an agency, citation handling from a medical-writing vendor, data verification from a CRO. The commissioner hands over requirements, approves the estimate, manages the schedule, and receives the finished work. The first thing to make clear is where "responsibility" resides along this flow.

This series stands consistently on one point: the work of production can be outsourced, but responsibility for the material released to the world cannot. However expert the vendor, it is the commissioner who decides "we release this under our company's name." That decision is nothing other than the acceptance of responsibility. So this series deals not with production technique but with what the commissioner must confirm, record, and judge before approving.

02Two Responsibilities That Remain After Outsourcing

The responsibility left with the commissioner has two layers of different character: regulatory and moral. They overlap but are not the same.

Regulatory responsibility is imposed by the Pharmaceutical and Medical Device Act and related norms: the ban on exaggerated advertising (§66), the ban on advertising pre-approval drugs (§68), and the duty of effort for appropriate information provision (§68-2). The Standards for Fair Advertising of Drugs, the guidelines for sales information provision activities, the JPMA Code and the JPMA creation guidance give these operational substance. None of them ask "who made it." They treat the matter as belonging to whoever released the non-compliant material. Misciting an article is fatal, so throughout this series we hold consistently to exaggeration = §66, pre-approval = §68, the duty of effort for information provision = §68-2. See the Pharmaceutical Act commentary and the Fair Advertising Standards.

Moral responsibility covers the territory the normative documents do not spell out. Because patients and clinicians trust materials as a basis for decisions, the stance of passing a misleading expression "because it is not a violation" is questioned before regulation ever enters. We address this head-on next time (Part 2: Moral Responsibility (in preparation)).

03For Whom This Is Written — The Assumed Commissioner

By "commissioner" this series means readers in the following roles. Titles vary by company, so we define by function.

What they share is a position where you do not produce with your own hands, yet you sit on the approval line that releases material to the world. Quality control of the actual production (the vendor side) is handled by the sister series "Production Quality Management." As its counterpart, this series describes the duties of the receiving and releasing side.

04What Counts as Material — Media Scope

Leaving the scope of duty vague creates the loophole "this isn't a material, so it needs no review." This series takes media broadly.

• Print (product brochures, explanatory materials, detail aids, patient booklets)
• Digital (product websites, banners, email, e-detailing, video)
• Academic / informational (disease-awareness materials, article abstracts, slide assets provided for lectures)
• MR support tools, Q&A sets, anticipated-question scripts
• Scripts that support social media and verbal explanation (talk guides)

The medium changes, but what the commissioner must ask does not: "Is this expression within the approved indication?" "Is the comparison or emphasis backed by evidence?" "Is the balance statement on adverse effects and contraindications sufficient?" Review routes per medium follow internal SOPs, but the verifying gaze is common to all.

05The Accidents Caused by "Passing It Straight Through"

The thing to avoid most is submitting a vendor's deliverable to internal review, or releasing it, without verification. This series calls it "passing it straight through." What happens when the commissioner leaves the middle gate open?

"Passing it straight through" is dangerous not because the quality is poor. It is because the very fact that the commissioner did not verify creates a vacuum of responsibility, both regulatory and moral. Even if the vendor made it correctly, if the only record is that the commissioner released it without checking, accountability cannot be met.

06The Line of Accountability with the Vendor

Outsourcing is not a transfer of responsibility but a division of roles. Where does the vendor's duty end and the commissioner's begin? The more this boundary is set in writing, the fewer the accidents.

What the table shows is that the duties of vendor and commissioner are doubled (made redundant). This is not waste but a safety device. The vendor secures the first pass; the commissioner verifies independently. A structure where the same item is checked twice by different parties catches what slips through. The moment the commissioner skips verification thinking "the vendor must have seen it," the doubling collapses and the safety device goes dead.

07The Commissioner's Four Duties

As the skeleton running through the whole series, we break the commissioner's duty into four actions. From Part 3 onward we translate these four into operational procedure.

1. Receipt — define and record what was received, when, and in which version. If receipt is vaguely defined, the starting point of verification is never fixed. (Part 3: The Receipt Flow (in preparation))
2. Verification — confirm indication scope, evidence, balance statements, and norm compliance against checklist items. Do not rely on personal "noticing"; itemize.
3. Judgment — decide pass or fail, settling on accept / conditional accept / return, each with its basis. A judgment template gives reproducibility.
4. Recording — document the course of verification, judgment, and sign-off so a third party can trace it later. The record is the last bastion of accountability.

08The Map and Scope of This Series

Part 1 (this piece) sets the principles and scope; Part 2 covers moral responsibility; from Part 3 we proceed through the receipt flow, verification checks, judgment templates, vendor inquiries, and record formats, closing with documentation in Part 10. Each part reads on its own, but the skeleton of the four duties is common to all.

Two notes on scope. First, this series does not replace internal SOPs or material-review regulations. Each company's rules take precedence; this series offers a practical lens that reinforces their operation. Second, take the fine points of norm interpretation to the primary sources. The Pharmaceutical Act, the Fair Advertising Standards, the sales information provision guidelines, the JPMA Code, and the JPMA creation guidance are the primary grounds; this series bridges how to read them from the commissioner's standpoint. Next time we take up the moral responsibility that sits before regulation — the boundary of "must not be released even if not a violation."